

Author Manuscript

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/cncr.33155](https://doi.org/10.1002/cncr.33155)

This article is protected by copyright. All rights reserved

DR. JOHN M. SALSMAN (Orcid ID : 0000-0003-2317-4006)

DR. SUZANNE C DANHAUER (Orcid ID : 0000-0002-2003-9805)

DR. JUSTIN B. MOORE (Orcid ID : 0000-0003-4059-0538)

DR. MOLLIE ROSE CANZONA (Orcid ID : 0000-0001-9351-5422)

DR. DAVID E. VICTORSON (Orcid ID : 0000-0002-3530-8633)

DR. BRYCE B. REEVE (Orcid ID : 0000-0002-6709-8714)

Article type : Commentary

Optimizing Measurement of Health-Related Quality of Life
in Adolescents and Young Adults with Cancer

John M. Salsman, PhD¹
Suzanne C. Danhauer, PhD¹
Justin B. Moore, PhD, MS²
Mollie R. Canzona, PhD^{1,3}
David E. Victorson, PhD⁴
Bradley J. Zebrack, PhD, MSW, MPH⁵
Bryce B. Reeve, PhD⁶

¹Department of Social Sciences and Health Policy, Wake Forest School of Medicine & the Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, USA

²Department of Implementation Science, Wake Forest School of Medicine & the Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, USA

³Department of Communication, Wake Forest University, Winston Salem, NC, USA

⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine & the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

⁵School of Social Work, University of Michigan, Ann Arbor, MI, USA

⁶Department of Population Health Sciences, Duke University School of Medicine & the Duke Cancer Institute, Durham, NC, USA

Funding Source: This publication was supported by the National Cancer Institute of the NIH under award number R01CA218398. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Conflict of Interest Disclosures: The authors have no disclosures.

Corresponding Author: John M. Salsman, Ph.D.
Medical Center Boulevard
Winston-Salem, NC 27157
336.713.3613 (phone), 336.716.7554 (fax)
jsalsman@wakehealth.edu

Running Head: Measuring HRQOL in AYAs: A PROMISing Approach

Portions of this manuscript were previously presented: Salsman JM, Canzona MR, Duckworth KE, Danhauer SC, Patel BG, Victorson D, Sanford SD, Ip EH, Little-Greene D, Howard DS, McLean TW, Zebrack B, Fingeret MC, Tucker-Seeley R, Clayman ML, Moore JB, Reeve BB. Designing conceptual frameworks for financial burden, body image, and fertility and parenthood within adolescent and young adult cancer survivors. Paper presented at the 3rd Global Adolescent & Young Adult Cancer Congress, Sydney, Australia (December 2018).

Precis: To date, the health-related quality of life experiences of adolescents and young adults are inconsistently and incompletely captured by existing patient-reported outcome (PRO) measures. The NIH PROMIS represents the state-of-the-art for measurement science of PROs and provides an optimal approach for addressing these measurement challenges and catalyzing future patient-centered research in AYA oncology.

Keywords: patient-reported outcomes, health-related quality of life, adolescent and young adult, measurement, oncology

COMMENTARY

Adolescence and young adulthood may be characterized as a time of becoming.¹ It is a time of significant personal and professional growth and of recognizing major life milestones such as graduations, jobs, and new relationships. Almost 90,000 adolescents and young adults (AYAs) in the United States are diagnosed with cancer annually,² experiencing it as a significantly distressing, widely disruptive, and singularly defining event in their lives. For AYAs with cancer, their “time of becoming” is often characterized by adapting to a wide-ranging number of challenges that compromise their physical, emotional, and social development and health-related quality of life (HRQOL).³⁻⁶ Their lives are less focused on life milestones and more on major

treatment milestones such as completing chemotherapy, receiving “clean” scans, and returning to work or school.⁷⁻¹⁰ Among AYAs, cancer is the most common disease-related cause of death for females, and second only to heart disease for males^{2,11} yet the vast majority of AYAs will survive their disease with the average five-year survival rate of >80%.¹²⁻¹⁴ Unfortunately, many AYA survivors report poorer HRQOL relative to their healthy peers^{3,4} and are at increased risks of cancer-related infertility, financial hardship, recurrence, second primary cancers, and symptom burden for late and long-term effects.¹⁵⁻¹⁷

Despite the unique needs and challenges of being diagnosed with and surviving cancer as an AYA, the HRQOL experiences of AYAs are rarely evaluated as part of clinical trials,¹⁸ and when they are assessed, they are inconsistently and incompletely captured by existing patient-reported outcome (PRO) measures. In 2013, the National Cancer Institute (NCI) held a State of the Science meeting to review and discuss current gaps in the evidence-base for AYA oncology across epidemiology, basic biology, clinical trials, health services and medical care, and HRQOL research.¹⁴ Key findings and future directions to advance AYA oncology research were summarized in a special “Adolescent and Young Adult Series” published in the spring of 2016 in the journal *Cancer*. Among the consensus recommendations for “next steps” from the HRQOL working group was the following: “Valid, reliable, developmentally relevant, and psychometrically robust measures of HRQOL, overall and by subdomain, are needed that cross the age spectrum and allow for studies of the full AYA age range.”¹⁴

More recently, the Childhood Cancer Data Initiative (CCDI) highlighted a similar need “to collect, analyze, and share data to address the burden of cancer in children and AYAs.”¹⁹ The CCDI has called for a better understanding of the barriers to PRO data collection in pediatric and AYA studies as well as increased use of valid and reliable assessment measures. Common barriers to completion of PROs can occur at both the patient and the clinic levels. At the patient level, factors that decrease completion rates can include respondent burden, measures that are not content or culturally relevant to the patient experience, or are poorly written (colloquial, double-barreled, or have high literacy levels), and are only available in English. At the provider/clinic level, PROs are not always integrated into the electronic medical record or the existing workflow, paper forms can be misplaced, and scoring of measures may not be interpretable or actionable. Collectively, these factors contribute to the relatively low yield of PRO data from AYAs to inform future research and cancer care.

In this commentary, our goal is to highlight the benefit of applying scale development methodologies from the NIH’s Patient-Reported Outcome Measurement Information System[®] (PROMIS[®]) to the field of HRQOL measurement among AYAs affected by cancer. This can be done in two ways: 1) using existing PROMIS measures that are relevant to the life experiences of AYAs, and 2) using PROMIS methodologies to developing new measures for AYAs where gaps in important HRQOL content domains exist. PROMIS represents state-of-the-art measurement

science of PROs and is an NIH Roadmap initiative designed to improve assessment of PROs using modern psychometric methods.^{20,21} The main focus of the PROMIS initiative has been on developing instruments to assess health status for chronic disease conditions across the age range from pediatrics to adults. Adapting the World Health Organization's tripartite framework of physical, mental, and social health,²² PROMIS has developed and calibrated measures to capture multiple areas of health and functioning²³⁻³¹ and has extensive evidence of its validity and reliability in both pediatric and adult cancer populations.³²⁻³⁹

HRQOL measurement in AYAs

AYAs with cancer represent a wide range of both disease types and developmental stages with a correspondingly wide range of HRQOL priorities. The most common cancer types among AYAs are breast, thyroid, hematologic malignancies, germ cell, and melanoma.⁴⁰ Developmentally, the AYA age group captures at least three distinct subgroups of adolescents (ages 15 to 17), emerging adults (ages 18 to 25), and young adults (ages 26 to 39).⁴¹ This level of disease and developmental heterogeneity results in an understandably broad range of HRQOL domains impacted by cancer and a lack of consensus regarding standardized assessment of HRQOL for AYAs. A recent systematic literature review identified the following core domains of HRQOL for AYAs: physical, cognitive, emotional, restricted activities, relationships with others, fertility, body image, and spirituality/outlook on life.⁴² In an observational study of developmentally diverse AYA patients and survivors, their most important HRQOL domains were physical function, pain, cognitive function, social support, and finances.^{43,44} The importance of individual HRQOL domains varied based on age subgroup and treatment status. Pain was more frequently ranked as a priority domain for on-treatment AYAs than for off-treatment AYAs, and finances were more commonly ranked by older AYAs. In the largest, population-based study of HRQOL in AYAs, the NCI's Adolescent & Young Adult Health Outcomes & Patient Experience (AYA HOPE) study,⁴⁵ the most common negative psychosocial life disruptions reported by AYAs (regardless of age cohort) were finances, body image, and fertility/parenthood.⁴⁶

Unfortunately, existing HRQOL measures for AYAs are often limited in several important ways: content that is not specific to AYAs' unique HRQOL needs or appropriate for their age group, questions that are not perceived to be relevant to AYAs, summary scores that lack meaningful reference values or norms, and questions that describe concepts in idiomatic or culturally-biased ways or are otherwise not translatable.^{43,47-49} Thus, there is a clear need for psychometrically-robust measures of HRQOL to be used with AYAs that capture meaningful constructs. Rather than reinvent the wheel, it is important to provide a clearer delineation of the appropriateness of existing HRQOL measurement frameworks and identify any existing gaps in HRQOL domains for AYAs with cancer. Existing measures of HRQOL may be generic, providing global evaluations of HRQOL across broad domains of physical, mental, and social health, or they may be cancer-specific, incorporating disease- and treatment-specific aspects of HRQOL. Further,

these measures may be developed for and validated with pediatric and adolescent populations (e.g., ages 8 to 17 years), or adult populations (18 years or older). Applying these tools for AYA research is challenging when the cohort crosses the common threshold of 18 years of age. Instead of using both pediatric and adult HRQOL measures for conducting research on AYAs, a single AYA HRQOL profile measure with a select number of short forms that captures the relevant HRQOL domains from 15 to 39 years of age would be ideal.

An informal review of generic and cancer-specific HRQOL measures for pediatric and AYA populations (Table 1) identified cross-cutting themes of physical, mental, and social HRQOL. Additional areas of relevance to AYAs' HRQOL are not easily captured by these three overarching themes and comprise a fourth category for "other" HRQOL concerns (e.g., school, work). Only two measurement frameworks cover the entire AYA age range from 15 to 39 years of age: the Pediatric Quality of Life Inventory (PedsQL)⁵⁰⁻⁵² which has separate, partially overlapping forms for adolescents, emerging adults, and young adults; and the Minneapolis-Manchester Quality of Life Survey of Health (MMQL),^{53,54} which has separate, non-parallel forms for adolescents and young adults. Notably, several important aspects of the AYA experience (i.e., financial burden,^{48,55} body image concerns,^{42,48} and fertility/parenthood concerns^{42,47}), are rarely and inconsistently measured by these measures.

Advantages of PROMIS

PROMIS includes over 300 measures of physical, mental, and social HRQOL from among 102 adult and 25 pediatric domains.⁵⁶ The PROMIS approach involves iterative steps of comprehensive literature searches, development of conceptual frameworks through concept elicitation interviews, identifying and categorizing items, qualitative assessment of items using focus groups and cognitive interviews, and quantitative evaluation of items using techniques from both classical test theory and item response theory.^{20,21,33,57-59} To assist developers in meeting the scientific standard criteria for assessing PROs, the PROMIS investigators created an Instrument Maturity Model.³³ This model describes the five stages of instrument development from latent trait or domain conceptualization to evidence of psychometric properties in multiple clinical samples (Figure 1).

What makes PROMIS stand apart from other established HRQOL measures is that each HRQOL domain measured by PROMIS is captured by an item bank. Other established HRQOL measures have a limited number of questions to assess each HRQOL construct (e.g., 6 questions on fatigue, 8 questions on physical functioning). The PROMIS item banks (one bank for each PRO) include a much larger number of questions that have undergone extensive testing using qualitative and quantitative methods. Every PROMIS measure draws a select number of questions from the item bank to provide a reliable and valid assessment of the HRQOL domain of interest. For example, selecting 10 fatigue questions out of the 95 fatigue questions in the PROMIS Fatigue item bank. PROMIS measures can be administered on paper or electronically

as fixed-length short forms. This version of the PROMIS measure means that everyone in the study answers the same set of questions (e.g., the 10-question fatigue measure). An alternate way to administer PROMIS measures is through computer adaptive testing (CAT). CAT-based assessment individually tailors the measure to each individual based on her/his responses to each question administered. Compared to fixed-length short forms, the CAT can reduce the number of questions being administered (e.g., maybe 5 instead of 10 questions) and achieve appropriately reliable measurement. Because all PROMIS measures (fixed-length short forms or CAT-based assessment) use items selected from the same PROMIS item bank, the scores can be compared or combined together across the measures.

A particular challenge within AYA HRQOL measurement is that both pediatric and adult perspectives are represented within the 15-39 age range. Previous testing of PROMIS measures was conducted with a broad age range (8-17 years and 18-99+ years) and did not include a specific focus on AYAs. Linking analyses provide an approach to “connect” the pediatric and adult forms in physical and emotional health domains.^{60,61} Alternatively, many of the adult items may prove reliable and valid for administration with older adolescents (ages 15 to 17) precluding the need for multiple forms. A unique strength of item banking and CAT is the flexibility in administration within a diverse sample. For example, younger and older AYAs may have different social health needs and priorities. A core set of items could be selected from within the PROMIS social health bank that can form a fixed-length short form across the entire AYA age range and be supplemented with additional items from the bank for specific age groups (younger vs older AYAs) to allow for greater measurement precision. This approach would provide tailoring at the item content level while also preserving comparability of scores within the full AYA age range.

Leveraging PROMIS standards and methodology is an important next step to improve assessment of HRQOL in AYAs with cancer. PROMIS can serve as a blueprint for researchers interested in developing new measures that have the same high standards as PROMIS as well as extending existing PROMIS measures to new clinical populations of interest (e.g., AYAs). Accordingly, developing new item banks to assess financial burden, body image concerns, and fertility/parenthood concerns among AYAs will allow the creation of optimal short forms and CATs. These tools should be designed following the PROMIS Scientific Standards⁵⁸ and related Consensus-based Standards for the selection of health Measurement Instruments (COSMIN).⁶²⁻⁶⁵ By adhering to this rigorous stepwise approach to PRO development and testing, PROMIS can be effectively used to address many of the challenges in measuring AYAs’ HRQOL (Table 2).

Conclusion

The NCI issued a clear call for a more psychometrically robust approach to measurement science in AYA oncology, a call that has been echoed by the Childhood Cancer Data Initiative. Advances in the development and validation of PROs for use with AYAs will strengthen

understanding of the patient experience and may ultimately contribute to a more efficient identification of AYA patients at risk for psychosocial distress and deleterious outcomes. There is growing awareness in the oncology field that PROs are valuable to capture the patient experience to evaluate treatment efficacy and safety and should be routinely collected in trials.⁶⁶⁻

⁷¹ Additional buy-in and sustained support from funding and regulatory agencies, and from leaders of oncology cooperative groups and review committees is needed to further catalyze PRO research in AYA oncology. A measurement system that is flexible, efficient, reliable, age-appropriate, relevant, comprehensible, interpretable, and translatable holds the potential to significantly elevate AYA clinical care and research pursuits. PROMIS provides this needed framework and approach to move this field forward.

Table 1 Common Measures and Domains for Assessing HRQOL in AYAs

	MMQL Adolescent & Young Adult Forms	PedsQL 4.0 Generic & 3.0 Cancer Module	PCQL-32 & PCQL Modular	LAYA-SRQL	IOC-CS
for ages:	13-20 & 21-45 years	13-18, 18-25, 25+ years	8-18 years	18-39 years	18-39 years
Physical	<ul style="list-style-type: none"> • Physical • Body Image 	<ul style="list-style-type: none"> • Physical Functioning • Pain and Hurt • Nausea • Perceived Physical Appearance 	<ul style="list-style-type: none"> • Disease and Treatment-Related Symptoms • Physical • Pain • Nausea 	<ul style="list-style-type: none"> • Vitality • Fertility 	<ul style="list-style-type: none"> • Body/Health
Mental	<ul style="list-style-type: none"> • Psychological • Outlook on Life • Cognitive Functioning 	<ul style="list-style-type: none"> • Emotional Functioning • Procedural Anxiety • Treatment Anxiety • Worry • Cognitive Problems 	<ul style="list-style-type: none"> • Psychological • Cognitive Functioning 	<ul style="list-style-type: none"> • Existential/ Spirituality • Coping • Cognition/ Memory 	<ul style="list-style-type: none"> • Personal Growth • Life Challenges • Thinking/Memory Problems
Social	<ul style="list-style-type: none"> • Social • Intimate Relations 	<ul style="list-style-type: none"> • Social Functioning • Communication 	<ul style="list-style-type: none"> • Social 	<ul style="list-style-type: none"> • Relationship • Dependence • Intimacy/ Sexuality 	<ul style="list-style-type: none"> • Talking with Parents • Socializing
Other		<ul style="list-style-type: none"> • School Functioning 		<ul style="list-style-type: none"> • Healthcare • Education/ Career 	<ul style="list-style-type: none"> • Health Literacy • Financial Problems

Note: Bold font indicates the presence of financial burden, body image, and fertility/parenthood dimensions captured by existing measures.

MMQL Adolescent = Minneapolis-Manchester Quality of Life instrument Adolescent form⁵³; MMQL Young Adult = Minneapolis-Manchester Quality of Life instrument Young Adult form⁵⁴

PedsQL 4.0 Generic = Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales⁵⁰; PedsQL 3.0 Cancer Module = Pediatric Quality of Life Inventory Cancer Module⁵¹

PCQL-32 = Pediatric Cancer Quality of Life Inventory-32⁷²; PCQL Modular = Pediatric Cancer Quality of Life Inventory-Modular⁷³

LAYA-SRQL=Late Adolescence and Young Adulthood-Survivorship-Related Quality of Life Scale⁷⁴

IOC-CS=Impact of Cancer scale for childhood cancer survivors⁷⁵

Figure Legend

Figure 1. PROMIS Instrument Maturity Model

Note: For additional details on the PROMIS Instrument Maturity Model, see

http://www.healthmeasures.net/images/PROMIS/PROMISStandards_Vers_2_0_MaturityModelOnly_508.pdf

Table 2 – AYA HRQOL Measurement Challenges and Potential Solutions

AYA HRQOL PRO measures need to be...	PROMIS provides...
Flexible	Fixed short forms or computer adaptive testing
Efficient	Minimal response burden by selecting most relevant questions
Reliable	Includes questions that demonstrate high ability to differentiate among individuals HRQOL levels.
Age-appropriate	Adult PROMIS questions are \leq 6 th grade reading level
Relevant	Wide range of HRQOL domains can be assessed by PROMIS*
Comprehensible	Vetted through cognitive interviews with a diverse sample of individuals in respect to age, education, race/ethnicity, and health status.
Interpretable	Uses easily interpretable T-score metric with reference scores to the US general population.
Translatable	Available in Spanish and other languages

Note: *PROMIS HRQOL domains overlap with the majority of important HRQOL domains for AYAs with the exception of financial burden, body image, and fertility/parenthood.

References

1. Mack JW. The PRISM intervention for adolescents and young adults with cancer: Paying attention to the patient as a whole person. *Cancer*. 2018;124(19):3802-3805.
2. American Cancer Society. Cancer Facts & Figures 2020. In: Atlanta, GA: American Cancer Society; 2020: <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html>.
3. Smith AW, Bellizzi KM, Keegan THM, et al. Health-related Quality of Life of Adolescent and Young Adult Cancer Patients in the United States: the AYA HOPE study. *J Clin Oncol*. 2013;31(17):2136-2145.
4. Salsman JM, Garcia SF, Yanez B, Sanford SD, Snyder MA, Victorson D. Physical, emotional, and social health differences between post-treatment young adults with cancer and matched healthy controls. *Cancer*. 2014;120(15):2247-2254.
5. Victorson D, Garcia SF, Sanford S, Snyder MA, Lampert S, Salsman JM. A Qualitative Focus Group Study to Illuminate the Lived Emotional and Social Impacts of Cancer and Its Treatment on Young Adults. *J Adolesc Young Adult Oncol*. 2019;8(6):649-659.
6. Husson O, Zebrack BJ, Block R, et al. Health-Related Quality of Life in Adolescent and Young Adult Patients With Cancer: A Longitudinal Study. *J Clin Oncol*. 2017;35(6):652-659.
7. Vetsch J, Wakefield CE, McGill BC, et al. Educational and vocational goal disruption in adolescent and young adult cancer survivors. *Psychooncology*. 2018;27(2):532-538.
8. Zebrack B, Kent EE, Keegan TH, Kato I, Smith AW. "Cancer sucks," and other ponderings by adolescent and young adult cancer survivors. *J Psychosoc Oncol*. 2014;32(1):1-15.
9. Keegan TH, Lichtensztajn DY, Kato I, et al. Unmet adolescent and young adult cancer survivors information and service needs: a population-based cancer registry study. *J Cancer Surviv*. 2012;6(3):239-250.
10. Ketterl TG, Syrjala KL, Casillas J, et al. Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors. *Cancer*. 2019.
11. Nass SJ, Beaupin LK, Demark-Wahnefried W, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop. *Oncologist*. 2015;20(2):186-195.
12. Keegan THM, Ries LAG, Barr RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. *Cancer*. 2016;122(7):1009-1016.
13. Moke DJ, Tsai K, Hamilton AS, et al. Emerging Cancer Survival Trends, Disparities, and Priorities in Adolescents and Young Adults: A California Cancer Registry-Based Study. *JNCI cancer spectrum*. 2019;3(2):pkz031.
14. Smith AW, Seibel NL, Lewis DR, et al. Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. *Cancer*. 2016;122(7):988-999.
15. Barr RD, Ferrari A, Ries L, Whelan J, Bleyer WA. Cancer in Adolescents and Young Adults: A Narrative Review of the Current Status and a View of the Future. *JAMA pediatrics*. 2016;170(5):495-501.
16. Smitherman AB, Anderson C, Lund JL, Bensen JT, Rosenstein DL, Nichols HB. Frailty and Comorbidities Among Survivors of Adolescent and Young Adult Cancer: A Cross-

- Sectional Examination of a Hospital-Based Survivorship Cohort. *J Adolesc Young Adult Oncol*. 2018;7(3):374-383.
17. Salsman JM, Bingen K, Barr RD, Freyer DR. Understanding, measuring, and addressing the financial impact of cancer on adolescents and young adults. *Pediatr Blood Cancer*. 2019:e27660.
 18. Pollock BH. What's Missing in the Assessment of Adolescent and Young Adult (AYA) Cancer Outcomes? *JNCI: Journal of the National Cancer Institute*. 2020.
 19. National Cancer Institute. Childhood Cancer Data Initiative (CCDI). 2020; <https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative>.
 20. DeWalt DA, Rothrock N, Yount S, Stone AA, PROMIS Cooperative Group. Evaluation of Item Candidates: The PROMIS Qualitative Item Review. *Med Care*. 2007;45(5 Suppl 1):S12-S21.
 21. Reeve BB, Hays RD, Bjorner JB, et al. Psychometric Evaluation and Calibration of Health-Related Quality of Life Item Banks: Plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). *Med Care*. 2007;45(5 Suppl 1):S22-S31.
 22. World Health Organization. Constitution of the World Health Organization. Geneva: World Health Organization; 1946.
 23. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS):depression, anxiety, and anger. *Assessment*. 2011;18(3):263-283.
 24. Garcia SF, Wagner LI, Choi S, George J, Cella D. PROMIS-compatible perceived cognitive function item banks for people with cancer. Paper presented at: Second Patient Reported Outcomes Measurement Information Systems (PROMIS) Conference; March, 2008; Bethesda, MD.
 25. Hahn EA, Devellis RF, Bode RK, et al. Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. *Qual Life Res*. 2010;19(7):1035-1044.
 26. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS sleep disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med*. 2011;10(1):6-24.
 27. Lai JS, Cella D, Choi S, Teresi JA, Hays RD, Stone AA. Developing a fatigue item bank for the Patient-Reported Outcomes Measurement Information System (PROMIS FIB version 1). Presented at the Meeting of the Survey Methods in Multicultural, Multinational, and Multiregional Contexts (3MC), Berlin, Germany. In:2008.
 28. Amtmann D, Cook KF, Jensen MP, et al. Development of a PROMIS item bank to measure pain interference. *Pain*. 2010;150(1):173-182.
 29. Revicki DA, Cook KF, Amtmann D, Harnam N, Chen WH, Keefe FJ. Exploratory and confirmatory factor analysis of the PROMIS pain quality item bank. *Qual Life Res*. 2013;Epub ahead of print.
 30. Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware Jr JE. The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. *J Clin Epidemiol*. 2014;67(5):516-526.

31. Weinfurt KP, Lin L, Bruner DW, et al. Development and Initial Validation of the PROMIS((R)) Sexual Function and Satisfaction Measures Version 2.0. *J Sex Med.* 2015;12(9):1961-1974.
32. Hinds PS, Nuss SL, Ruccione KS, et al. PROMIS pediatric measures in pediatric oncology: valid and clinically feasible indicators of patient-reported outcomes. *Pediatr Blood Cancer.* 2013;60(3):402-408.
33. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. *J Clin Oncol.* 2007;25(32):5106-5112.
34. Flynn KE, Lin L, Cyranowski JM, et al. Development of the NIH PROMIS Sexual Function and Satisfaction measures in patients with cancer. *J Sex Med.* 2013;10 Suppl 1:43-52.
35. Reeve BB, McFatrigh M, Mack JW, et al. Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment. *Pediatr Blood Cancer.* 2020;67(4):e28160.
36. Hinds PS, Wang J, Cheng YI, et al. PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology. *Pediatr Blood Cancer.* 2019;66(5):e27606.
37. Reeve BB, Edwards LJ, Jaeger BC, et al. Assessing responsiveness over time of the PROMIS((R)) pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease. *Qual Life Res.* 2018;27(1):249-257.
38. Jensen RE, Potosky AL, Reeve BB, et al. Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. *Qual Life Res.* 2015;24(10):2333-2344.
39. Jensen RE, King-Kallimanis BL, Sexton E, et al. Measurement properties of PROMIS Sleep Disturbance short forms in a large, ethnically diverse cancer cohort. *Psychological Test and Assessment Modeling.* 2016;58(2):353-370.
40. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. *Nat Rev Cancer.* 2008;8(4):288-298.
41. Arnett JJ. Emerging adulthood: A theory of development from the late teens through the twenties. *Am Psychol.* 2000;55(5):469.
42. Sodergren SC, Husson O, Robinson J, et al. Systematic review of the health-related quality of life issues facing adolescents and young adults with cancer. *Qual Life Res.* 2017;26(7):1659-1672.
43. Salsman J, Snyder M, Zebrack B, Reeve B, Chen E. Measuring quality of life in adolescents and young adults (AYAS) with cancer: A promising solution? *Ann Behav Med.* 2016;50 Suppl 1:1-335.
44. Siembida EJ, Reeve BB, Zebrack BJ, Snyder MA, Salsman JM. Measuring health-related quality of life in adolescents and young adult (AYA) cancer survivors with the NIH PROMIS®: Comparing adolescent, emerging adult, and young adult survivor perspectives. under review. 2020.
45. Smith AW, Keegan T, Hamilton A, et al. Understanding care and outcomes in adolescents and young adult with Cancer: A review of the AYA HOPE study. *Pediatr Blood Cancer.* 2019;66(1):e27486.

46. Bellizzi KM, Smith A, Schmidt S, et al. Positive and negative psychosocial impact of being diagnosed with cancer as an adolescent or young adult. *Cancer*. 2012;118(20):5155-5162.
47. Quinn GP, Huang IC, Murphy D, Zidonik-Eddelton K, Krull KR. Missing content from health-related quality of life instruments: interviews with young adult survivors of childhood cancer. *Qual Life Res*. 2013;22(1):111-118.
48. Quinn GP, Goncalves V, Sehovic I, Bowman ML, Reed DR. Quality of life in adolescent and young adult cancer patients: a systematic review of the literature. *Patient Relat Outcome Meas*. 2015;6:19-51.
49. Clinton-McHarg T, Carey M, Sanson-Fisher R, Shakeshaft A, Rainbird K. Measuring the psychosocial health of adolescent and young adult (AYA) cancer survivors: a critical review. *Health Qual Life Outcomes*. 2010;8:25.
50. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales in Healthy and Patient Populations. *Med Care*. 2001;39(8):800-812.
51. Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL in pediatric cancer: Reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. *Cancer*. 2002;94(7):2090-2106.
52. Robert RS, Paxton RJ, Palla SL, et al. Feasibility, reliability, and validity of the pediatric quality of life inventory™ generic core scales, cancer module, and multidimensional fatigue scale in long-term adult survivors of pediatric cancer. *Pediatr Blood Cancer*. 2012;59(4):703-707.
53. Bhatia S, Jenney ME, Bogue MK, et al. The Minneapolis-Manchester Quality of Life instrument: reliability and validity of the Adolescent Form. *J Clin Oncol*. 2002;20(24):4692-4698.
54. Bhatia S, Jenney ME, Wu E, et al. The Minneapolis-Manchester Quality of Life instrument: Reliability and validity of the Youth Form. *J Pediatr*. 2004;145(1):39-46.
55. Tucker-Seeley RD, Yabroff KR. Minimizing the "financial toxicity" associated with cancer care: advancing the research agenda. *J Natl Cancer Inst*. 2016;108(5).
56. HealthMeasures. HealthMeasures: Transforming how health is measured. 2017; <http://www.healthmeasures.net/index.php>. Accessed January 18, 2017.
57. Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH Roadmap Cooperative Group During its First Two Years. *Med Care*. 2007;45(5 Suppl 1):S3-S11.
58. PROMIS Health Organization and PROMIS Cooperative Group. PROMIS® Instrument Development and Validation: Scientific Standards Version 2.0 (revised May 2013). 2013; http://www.nihpromis.org/Documents/PROMISStandards_Vers2.0_Final.pdf.
59. Lasch KE, Marquis P, Vigneux M, et al. PRO development: rigorous qualitative research as the crucial foundation. *Qual Life Res*. 2010;19(8):1087-1096.
60. Tulsy DS, Kisala PA, Boulton AJ, et al. Determining a transitional scoring link between PROMIS® pediatric and adult physical health measures. *Qual Life Res*. 2019;28(5):1217-1229.
61. Reeve BB, Thissen D, DeWalt DA, et al. Linkage between the PROMIS® pediatric and adult emotional distress measures. *Qual Life Res*. 2016;25(4):823-833.

62. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. *Qual Life Res.* 2011;21(4):651-657.
63. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res.* 2010;19(4):539-549.
64. Mokkink LB, Terwee CB, Knol DL, et al. Protocol of the COSMIN study: COnsensus-based Standards for the selection of health Measurement INstruments. *BMC Med Res Methodol.* 2006;6:2.
65. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. *BMC Med Res Methodol.* 2010;10:22.
66. St Germain D, Denicoff A, Torres A, et al. Reporting of health-related quality of life endpoints in National Cancer Institute–supported cancer treatment trials. *Cancer.* 2020;126(11):2687-2693.
67. Basch E. The missing voice of patients in drug-safety reporting. *N Engl J Med.* 2010;362(10):865-869.
68. Au H-J, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. *Expert Rev Pharmacoecon Outcomes Res.* 2010;10(2):119-128.
69. Secord AA, Coleman RL, Havrilesky LJ, Abernethy AP, Samsa GP, Cella D. Patient-reported outcomes as end points and outcome indicators in solid tumours. *Nat Rev Clin Oncol.* 2015;12(6):358-370.
70. Cella D. In our patient-centered era, it is time we gave patient-reported outcomes their due. *Cancer.* 2020;126(11):2592-2593.
71. Smith AB, Cocks K, Parry D, Taylor M. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G). *Qual Life Res.* 2014;23(3):971-976.
72. Varni JW, Katz ER, Seid M, Quiggins DJ, Friedman-Bender A. The pediatric cancer quality of life inventory-32 (PCQL-32): I. Reliability and validity. *Cancer.* 1998;82(6):1184-1196.
73. Seid M, Varni JW, Rode CA, Katz ER. The Pediatric Cancer Quality of Life Inventory: a modular approach to measuring health-related quality of life in children with cancer. *Int J Cancer Suppl.* 1999;12:71-76.
74. Park C, Wortmann J, Hale A, Cho D, Blank T. Assessing quality of life in young adult cancer survivors: development of the Survivorship-Related Quality of Life scale. *Qual Life Res.* 2014;23(8):2213-2224.
75. Zebrack BJ, Donohue JE, Gurney JG, Chesler MA, Bhatia S, Landier W. Psychometric evaluation of the impact of cancer (IOC-CS) scale for young adult survivors of childhood cancer. *Qual Life Res.* 2010;19(2):207-218.

